Key Takeaway: Precision BioSciences, Inc. has announced it will report its financial results for the first quarter of 2026 on May 5, 2026. The company is known for its proprietary ARCUS gene editing platform, which aims to develop therapies for genetic and infectious diseases. This announcement comes as the company continues to work on its clinical stage candidates.
Price reaction · baseline $6.9 (2026-04-29 close) · hit after-hours · 1 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+3.6%
Market Sentiment Analysis
POSITIVE FACTORS
Precision BioSciences is advancing its innovative ARCUS platform.
The company is focused on addressing high unmet medical needs.
Upcoming financial results may indicate progress in their clinical pipeline.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS®platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the first quarter 2026 and provide a business update on May 5, 2026.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS®genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of clinical stage in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visitwww.precisionbiosciences.com.
The ARCUS®platform is being used to developin vivogene editing therapies for sophisticated gene edits, including gene elimination (removing a genome e.g. viral DNA such as in the Company’s PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company’s PBGENE-DMD program) and gene insertion (inserting DNA into gene to cause expression/add function).
Frequently Asked Questions
When will Precision BioSciences report its Q1 2026 results?
Precision BioSciences will report its Q1 2026 financial results on May 5, 2026.
What is the ARCUS platform used for?
The ARCUS platform is used to develop in vivo gene editing therapies for various diseases.
What types of therapies is Precision BioSciences developing?
The company is developing therapies for genetic and infectious diseases using its ARCUS platform.
What does the ARCUS platform aim to achieve?
The ARCUS platform aims to deliver lasting cures for diseases with no adequate treatments.